CCP
AEGR

Clough Capital Partners’s Aegerion Pharmaceuticals AEGR Stock Holding History

Clough Capital Partners’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-255,500
Closed -$6.69M – 256
2015
Q1 		$6.69M Sell
255,500
-9,800
-4% -$249K 0.22% 121
2014
Q4 		$5.55M Sell
265,300
-97,800
-27% -$2.46M 0.2% 118
2014
Q3 		$12.1M Sell
363,100
-145,700
-29% -$4.52M 0.45% 76
2014
Q2 		$16.3M Buy
+508,800
New +$18.9M 0.52% 77

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Clough Capital Partners's AEGR Position: Q2 2015 in Review

Clough Capital Partners sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2015, closing a stake of 255,500 shares — an estimated $6.69M sold.

Clough Capital Partners first reported a position in AEGR in Q2 2014 and held it in 4 quarters. The position peaked at $16.3M in Q2 2014. 97 funds tracked by Wall St. Rank hold AEGR as of Q2 2015.

  • Clough Capital Partners reported no remaining Aegerion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Clough Capital Partners sold 255,500 Aegerion Pharmaceuticals shares in Q2 2015, an estimated $6.69M.
  • Clough Capital Partners first reported a position in Aegerion Pharmaceuticals in Q2 2014 and held it in 4 quarters.
  • Clough Capital Partners's Aegerion Pharmaceuticals position peaked at $16.3M in Q2 2014.
  • 97 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2015.

Based on Clough Capital Partners's 13F filing for Q2 2015, filed 14 Aug 2015.